Literature DB >> 27659027

Variability in Response to Intravenous Immunoglobulin in the Treatment of Kawasaki Disease.

Mallory L Downie1, Cedric Manlhiot2, Giuseppe A Latino3, Tanveer H Collins2, Nita Chahal2, Rae S M Yeung3, Brian W McCrindle2.   

Abstract

OBJECTIVES: To characterize the pattern of temperature response to intravenous immunoglobulin (IVIG) infusion in patients with Kawasaki disease (KD). STUDY
DESIGN: Patients nonresponsive to IVIG (axillary temperature ≥37.5°C >24 hours after end of IVIG) were identified. Each patient with IVIG-nonresponsive KD was matched to a control patient with IVIG-responsive KD of the same age, sex, and duration of fever before IVIG. Hourly temperature profiles were obtained from immediately before the start of IVIG infusion until complete defervescence.
RESULTS: A total of 182 patients nonresponsive to IVIG were matched (total n = 364). Nonresponders were further classified as partial nonresponders (68%) (axillary temperature decreased to <37.5°C but fever recurred) and complete nonresponders (32%) (axillary temperature consistently ≥37.5°C throughout IVIG treatment). The temperature profile during IVIG infusion was similar between responders and partial nonresponders (EST: -0.061 [0.007]°C/h, P < .001 for responders vs EST: -0.027 (0.012)°C/h, P = .03 for partial nonresponders [responders vs partial nonresponders, P = .65]), where EST is the parameter estimate from the regression model, representing the change in degrees Celsius for each hour since start of IVIG. In complete nonresponders, IVIG was not associated with significant decreases in temperature (EST: -0.008 [0.010]°C, P = .42). Factors associated with complete (vs partial) nonresponse included laboratory-confirmed infection, greater C-reactive protein, and IVIG brand. Defervescence in partial nonresponders was achieved with a second IVIG dose for 72% of patients compared with 58% of complete nonresponders (P = .001). Complete nonresponders were more likely to develop coronary artery aneurysms vs partial nonresponders (OR: 2.4 [1.1-5.4], P = .03) or responders (OR: 3.2 [1.5-6.9], P = .002).
CONCLUSIONS: Nonresponse to initial IVIG can be further characterized by temperature profile, and complete nonresponders may require more aggressive second-line therapy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  inflammatory heart disease; pediatrics; resistance; risk factors

Mesh:

Substances:

Year:  2016        PMID: 27659027     DOI: 10.1016/j.jpeds.2016.08.060

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

1.  Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial.

Authors:  Michael A Portman; Nagib S Dahdah; April Slee; Aaron K Olson; Nadine F Choueiter; Brian D Soriano; Sujatha Buddhe; Carolyn A Altman
Journal:  Pediatrics       Date:  2019-05-02       Impact factor: 7.124

2.  Factors Predicting Resistance to Intravenous Immunoglobulin and Coronary Complications in Kawasaki Disease: IVIG Resistance in Kawasaki Disease.

Authors:  Ji Whan Han
Journal:  Korean Circ J       Date:  2018-01       Impact factor: 3.243

Review 3.  Kawasaki disease: pathophysiology and insights from mouse models.

Authors:  Magali Noval Rivas; Moshe Arditi
Journal:  Nat Rev Rheumatol       Date:  2020-05-26       Impact factor: 20.543

4.  Kawasaki Disease Complicated by Salmonella oranienburg Coinfection.

Authors:  Zachary Barbara; Savannah P Ellenwood; Emily D Loe; Joon Choi; Kathleen Ryan; Nancy Joseph
Journal:  Case Rep Pediatr       Date:  2021-04-02

Review 5.  Correct identification of incomplete Kawasaki disease.

Authors:  Tianhua Li; Jie Feng; Na Li; Tingting Liu
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

6.  High-Concentration Intravenous Immunoglobulin May Influence the Course of Fever and Rate of Reported Treatment Resistance in Children With Kawasaki Disease: A Single-Center Retrospective Analysis.

Authors:  Seung Beom Han; Woosuck Suh; Jung-Woo Rhim
Journal:  Paediatr Drugs       Date:  2022-09-26       Impact factor: 3.930

7.  Combined Single Nucleotide Variants of ORAI1 and BLK in a Child with Refractory Kawasaki Disease.

Authors:  Saki Kanda; Yoshimitsu Fujii; Shin-Ichiro Hori; Taichi Ohmachi; Ken Yoshimura; Koichiro Higasa; Kazunari Kaneko
Journal:  Children (Basel)       Date:  2021-05-21

8.  Profile of resistance to IVIG treatment in patients with Kawasaki disease and concomitant infection.

Authors:  Audrey Dionne; Cathie-Kim Le; Steffany Poupart; Julie Autmizguine; Léamarie Meloche-Dumas; Jean Turgeon; Anne Fournier; Nagib Dahdah
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

9.  Clinical characteristics of Kawasaki disease and concurrent pathogens during isolation in COVID-19 pandemic.

Authors:  Yue-Yue Ding; Yan Ren; Jie Qin; Guang-Hui Qian; Yun-Jia Tang; Ye Chen; Xuan Li; Lei Xu; Chun-Hong Qiao; Ling Sun; Hai-Tao Lv
Journal:  World J Pediatr       Date:  2021-06-23       Impact factor: 2.764

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.